Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24 Clinical Trial Not Allowed)
ID: 352967Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352967

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-007.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 14, 2024 12:00 AM
  4. 4
    Due Jul 8, 2024 12:00 AM
Description

The National Institutes of Health (NIH) is offering a limited competition grant opportunity for a Research Resource for Natural Product Nuclear Magnetic Resonance (NMR) Data. This grant aims to support the sustainability, scaling, and wider community inclusiveness of an established NMR research resource. The resource consists of raw and meta-data from natural products, ranging from crude extracts to purified substances, and has the capacity to upload, download, store, search, and analyze raw NMR data. The purpose of this grant is to promote research in the field of natural products and advance the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. The grant does not require cost sharing or matching and is open to various eligible applicants. The closing date for applications is July 8, 2024. For more information and to apply, please visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-007.html.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AT-24-007-Full-Announcement.html
4/10/2024
Similar Opportunities
NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)". This grant aims to support investigator-initiated, early phase, clinical trials of natural products, including botanicals, probiotics, and dietary supplements. The trials should have a strong scientific premise and provide valuable information for further clinical testing and development of the natural product. The grant provides up to three years of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product's effect on a specified target measure. If milestones are achieved, additional support may be awarded to replicate the impact of the natural product on target engagement and assess its association with clinical outcomes. The grant does not require cost sharing or matching. The deadline for applications is November 13, 2026. For more information and to apply, visit the NIH grants website at [http://grants.nih.gov/grants/guide/pa-files/PAR-24-124.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-124.html).
Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)". This opportunity falls under the category of Health and is a Cooperative Agreement. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant aims to support a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, administrative support, data management, and biostatistical support for the proposed clinical trial. The clinical trial must be relevant to the research mission of the NCCIH (National Center for Complementary and Integrative Health) and considered a high priority by the Center. Applicants are encouraged to consult the NCCIH website for additional information about the mission, strategic vision, and research priorities of the Center. It is strongly recommended that applicants contact the appropriate Scientific/Research contact for the area of science they are planning to develop an application for prior to submitting to this grant opportunity. The application must include a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Failure to include a PEDP will result in the application being considered incomplete and withdrawn. For more information and to access the full opportunity announcement, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-125.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-125.html). Any further inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)". This opportunity falls under the category of Health and is a Cooperative Agreement funding instrument type. The grant aims to support the discovery and development of safe, nontoxic, and efficacious natural products for cancer interception and prevention. The UG3 phase of the initiative focuses on selecting clinically relevant targets and developing and validating assays for bioactivity and toxicity screening. On the other hand, the UH3 phase involves screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents. The grant does not require cost sharing or matching. The maximum award ceiling is $250,000. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, Non-domestic (non-U.S.) Entities (Foreign Institutions) and non-U.S. components of U.S. Organizations are not eligible to apply. The close date for this grant opportunity is June 13, 2025, and the archive date is July 19, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-028.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-028.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is seeking applications for a Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products. This opportunity falls under the category of Health and is a Cooperative Agreement. The purpose of this funding is to support investigator-initiated, multi-site clinical trials to study the effects of natural products in NCCIH designated areas of high research priority. Natural products include botanicals, probiotics, and products marketed as dietary supplements. The Clinical Coordinating Center will be responsible for developing and implementing the proposed multi-site clinical trial. This includes project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. The funding mechanism for this opportunity is a two-phase, milestone-driven, cooperative agreement (UG3/UH3). Applicants are also required to submit a Data Coordinating Center application for data analysis and management. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for submission is July 14, 2026. For more information and to apply, please visit the NIH website at [http://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html).
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award, a grant opportunity for investigator-initiated, early phase, clinical trials of natural products. Natural products in this context refer to botanicals, dietary supplements, and probiotics that have a strong scientific premise for further clinical testing. The grant will provide up to 3 years of support for studies that replicate the impact of the natural product on target engagement in humans and assess the association between the degree of impact and functional or clinical outcomes in a patient population. The trials should be hypothesis-based, milestone-driven, and aligned with the research priorities and mission of NCCIH. This funding mechanism aims to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing. Efficacy or effectiveness trials will not be supported. For more information, visit the [NIH grants website](https://grants.nih.gov/grants/guide/pa-files/PAR-24-116.html).